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Abstract
Background: to investigate the value of using preoperative neutrophil to lymphocyte and platelet to lymphocyte
levels in the patients of borderline ovarian tumors.
Methods: During the period between January 2002 and December 2015, the pathology reports and archival
files of the Gynecologic Oncology Department of Çukurova University Medical Hospital and the Gynecologic
Oncology Department of Dumlupınar University, Evliya Çelebi Education and Research Hospital were
retrospectively reviewed, and 144 patients of borderline ovarian tumor (as the study group) and 123 patients
of serous cystadenoma (as the control group) were determined for eligibility in this study. Data regarding
age, menopausal status, preoperative ultrasound findings, ca125 and complete blood counts were reviewed.
Neutrophil to lymphocyte and platelet to lymphocyte ratios were calculated and these parameters were
statistically compared between the groups.
Results: There was a statistically significant difference between the groups according to neutrophil count,
platelet count, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio; in addition to age, ca125
and preoperative ultrasound findings.
Conclusions: It seems that neutrophil to lymphocyte and platelet to lymphocyte ratios are useful in
predicting borderline ovarian tumors, preoperatively. However, further prospective studies are needed.
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Background
Borderline ovarian tumors (BOTs) are characterized with
atypical epithelial proliferation without stromal invasion
and they comprise about 10–15 % of primary epithelial
ovarian neoplasms [1]. Compared with epithelial ovarian
carcinomas (EOCs), BOTs are usually determined at
early stages and presented in premenopausal women.
Surgery is the mainstay of the treatment and frequently
curable with excellent prognosis [2]. Due to the absence
of specific preoperative criteria for BOTs, diagnosis is
often made by the pathological examinations of the sur-
gical specimens. Findings of imaging methods and ca
125 measurements may indicate suspicious pelvic mass
without specifying whether it is invasive or borderline
tumor [3]. Distinguishing these tumors (borderline or
invasive) from the benign ones is extremely significant
in order to skip over the incomplete surgery which
results in poor prognosis [4].
Inflammation has a significant role in the development
of numerous cancers by various mechanisms such as;
up-regulation of cytokines and inflammatory mediators,
inhibition of apoptosis, induction of angiogenesis and
stimulation of DNA damage. In addition, immune function
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is compromised by systemic inflammatory response (SIR)
mediators which then increase the leukocytes, neutrophils,
platelets, C reactive protein (CRP) and fibrinogen concen-
trations. On the other hand, they decrease the lymphocyte
level. Platelets can also be increased by the thrombocytosis
induced by cancer. As preoperative inflammatory markers,
neutrophil-to-lymphocyte ratio (NLR) and platelet-to-
lymphocyte ratio (PLR) have been suggested to be useful
for discriminating malignant and benign ovarian tumors.
NLR and PLR are noninvasive, easily measured, universally
known and cost-effective markers [5–7].
To the best of our knowledge, although NLR and
PLR levels (as preoperative markers) have been the
subject of many studies concerning ovarian cancers,
no specific studies associated with BOTs were found.
Therefore, in the present study, we have aimed to in-
vestigate the value of using these markers prior to
surgery in the patients of BOT.
Methods
This retrospective study was conducted at the Gyne-
cologic Oncology Department of Çukurova University
Medical Hospital in Adana, Turkey and the Gyneco-
logic Oncology Department of Dumlupınar University,
Evliya Çelebi Education and Research Hospital in
Kütahya, Turkey. The study was approved by The
Research Ethics Committee of Çukurova University.
Gynecologic Oncology Unit records and pathology re-
ports of the two centers were reviewed retrospectively
for the period between 01 January 2002 and 30
December 2015. During this period, 116 cases from
Çukurova University (ÇU) and 28 cases from Dumlupınar
University (DPU); a total of 144 patients of BOT, and
as control group a total of 123 patients of serous
cystadenoma (98: from ÇU, 25: from DPU) were
detected to be eligible for the study criteria. Clinical
data such as age, menopausal status, preoperative
ultrasound findings (presence of septa, papillary for-
mation and ascites) ca125 and complete blood counts
(CBC) were obtained from the hospital database net-
work and archival files of the patients. Neutrophil,
platelet, monocyte, hemoglobin and hematocrit pa-
rameters were attained from the CBC profile. These
parameters were recorded separately and then NLR
and PLR were calculated. The NLR was considered to
be the absolute neutrophil count divided by the abso-
lute lymphocyte count, and the PLR was defined as
the absolute platelet count divided by the absolute
lymphocyte count. Patients whose blood samples were
not taken within a week before surgery were excluded
from the study population. Also, patients with in-
creased white blood cell count that might reflect a
coexisting infection were not included. A story of
hematological malignancies or other hematological
and autoimmune disorders was the other exclusion
criterion. According to the clinical and pathological
assessments a total of 267 cases (study group: 144
BOT and control group: 123 serous cystadenoma)
comprised the study population. Two groups were com-
pared according to the aforementioned parameters.
Statistical methodology: Continuous variables were
presented as mean, median and standard deviation (SD).
Chi-square (χ2) test evaluated associations between the
categorical and continuous variables. Mann-Whitney U
and Wilcoxon W tests were performed for the multiple
comparisons between variables. The receiver operating
characteristic (ROC) curve analysis was carried out to
analyze the discriminative role of variables. P values
were considered statistically significant at p < 0.05. SPSS
22.0 Evaluation Version (Statistical Package for Social
Sciences, Chicago, IL, USA) software package was used
for the statistical analysis.
Results
The study enrolled a total of 267 patients; 144 with BOT as
the study group and 123 with serous cystadenoma (SCA)
as the control group. These patients’ distribution was as the
following; 116 cases of BOT and 98 cases of SCA from ÇU,
28 cases of BOT and 25 cases of SCA from DPU. Patho-
logical Evaluations of the specimens were performed by ex-
pert gynecologic pathologists in the same institutions.
Mean age of BOT patients was 41.3 ± 14.7 lower
than SCA patients (48.7 ± 16.8) (p = 0.000). Most of
the BOT patients (72.2 %) and about half of the
SCA patients (51.2 %) were premenopausal. Histo-
logic distribution of the BOT cases was as the fol-
lowing; 94 patients (65 %) with serous, 50 (35 %)
with mucinous histology. Patients’ clinicopathological
characteristics are shown in Table 1.
In the preoperative assessment with ultrasonography;
septa pattern was found to be positive in 78 (54.2 %)
cases, papilla formation in 111 (77.1 %) and ascites in 35
(24.3 %) of the BOT patients. Nonetheless, all of
these parameters were almost negative in the SCA
group (p = 0,000). While the median of ca125 value
was 86 (4–2878) in BOT patients, it was 25 (4–429)
in the SCA group (p = 0,000).
From blood count parameters; neutrophil, monocyte,
platelet, hemoglobin and hematocrit were evaluated
separately. Although, mean and median of the monocyte
count of the BOT cases were higher than those of the SCA
cases, no statistically significant difference was observed ac-
cording to the monocyte count between groups (p = 0.081).
Median of the neutrophils count was 6470 (1040–22300) in
the BOT group and 5300 (1700–18700) in the SCA
patients. This difference was statistically significant
(p = 0.001). Also, hemoglobin and hematocrit values
were statistically significant when compared between
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groups (p = 0.004). On the other hand, the difference
of platelets count between groups appeared to have
the tendency to be statistically significant (p = 0.05).
Median of NLR was 2.5 (0.28–15.5) and 2.0 (0.97–7.2) in
the BOT and SCA patients, respectively. This difference
regarding the NLR between the study and control groups
was detected to be statistically significant (p = 0.000). Me-
dian of PLR was 133(54.7–289.5) in the BOT cases,
whereas it was 128.5 (39–198) in the SCA patients. When
compared between groups, results according to the
PLR was determined to be statistically significant,
also (p = 0.039). Comparison between the groups ac-
cording to the hematologic variables is demonstrated
in Table 2. ROC curve analyses were applied to
estimate the cut-off values of the NLR and PLR. The
recommended cut-off value of NLR in terms of pre-
dicting BOT was found to be 2.2 (sensitivity: 66 %, speci-
ficity: 60 %). The AUC was 0.661 ± 0.033 (95 % CI: 0.595–
0.726) (p = 0.000). On the other hand, when a cut-off value
of 122.2 was considered for PLR, the sensitivity and speci-
ficity were calculated as 57 and 40 %, respectively.
The AUC for PLR was 0.573 ± 0.035 (95 % CI: 0.505–
0.642, p = 0.039) (Fig. 1a). Furthermore, NLR and PLR
values of BOT cases were divided according to their
histopathological types as serous BOTs (SBOT) and
mucinous BOTs (MBOT). While median of NLR and
PLR was 2.6 (1.03–15.5) and 136.9 (54.7–289.5) for
SBOT, it was 2.48 (0.28–13.5) and 118.42 (65.23–238.4)
for MBOT, respectively. Thereafter, these values were
compared individually with the NLR and PLR values of
the SCA cases (control group), and ROC curve analyses
were performed. In the comparison between SBOT and
SCA, both of NLR (p = 0.000) and PLR (p = 0.005) were
detected to be with statistically significant discriminative
value. The sensitivity and specificity were determined to
be 66 % and 60 %, respectively, when a cut-off value by 2.2
of NLR was recommended in identifying SBOT, preopera-
tively (AUC: 0.675 ± 0.037, 95 % CI: 0.603–0.747). For
PLR; a cut-off value of 122.2 was found to be with 62 % of
sensitivity and 40 % of specificity in discriminating
SBOT cases, preoperatively (AUC: 0.612 ± 0,040, 95 %
CI: 0.534–0.690), (Fig. 1b). Whereas; the difference of
NLR between MBOT and SCA patients was established to
be statistically significant (p = 0.006), the difference of PLR
between these groups was not (p = 0.984). Similar in the all
BOT and SBOT patients, the sensitivity and specificity were
detected to be 66 % and 60 %, respectively, when a cut-off
value by 2.2 of NLR was considered in predicting MBOT,
preoperatively (AUC: 0.633 ± 0.047, 95 % CI: 0.541–0.726),
(Fig. 1c). A scatter graph of NLR and PLR regarding to the
histopathological types is demonstrated in Fig. 2.
Table 1 Patients’ clinicopathological characteristics
GROUP
Borderline tumor Serous cystadenoma
N% N% P
Menopausal status
Premenopausal 104 (72,2) 63 (51,2) 0,000
Postmenopausal 40 (27,8) 60 (48,8)
Histological type
Serous 94 (65) 123 (100,0)
Mucinous 50 (35) 0 (,0)
Septa
No 66 (45,8) 121 (98,4) 0,000
Yes 78 (54,2) 2 (1,6)
Papilla
No 33 (22,9) 121 (98,4) 0,000
Yes 111 (77,1) 2 (1,6)
Ascites
No 109 (75,7) 123 (100,0) 0,000
Yes 35 (24,3) 0 (,0)
Table 2 Comparison of patients’ age, ca125 and hematologic variables between the groups
Parameter GROUP P
Borderline tumor Serous cystadenoma
Mean Standard Deviation Median Minimum-Maximum Mean Standard Deviation Median Minimum-Maximum
Age 41,3 14,7 39 14–80 48,7 16,8 49 17–84 0,000
ca125 170,5 301,5 86 4–2878 32,9 50,0 25 4–429 0,000
NLR 3,8 3,3 2,50 0,28–15,5 2,3 1,3 2,00 0,97–7,20 0,000
PLR 138,4 55,7 133 54,7–289,5 119,7 34,1 128,50 39–198 0,039
Monocyte 6101,6 3375,2 6345 1600–40000 5498,7 1866,6 4890 560–9030 0,081
Neutrophil 7694,6 4528,6 6470 1040–22300 5892,7 3013,7 5300 1700–18700 0,001
Platelet 293186,2 90934,4 294000 90000–531000 277000 74069,7 275000 100000–584000 0,050
Hemoglobin 12,5 8,6 11,90 7,4–11,25 11,2 1,8 11,20 7,3–15 0,004
Hematocrit 38,3 28,8 35,75 25,9–46 38,9 36,9 33,70 24,4–47,6 0,004
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Fig. 1 a ROC curve for neutrophil to lymphocyte and platelet to lymphocyte ratios between all BOT and SCA cases. b ROC curve for neutrophil
to lymphocyte and platelet to lymphocyte ratios between SBOT and SCA cases. c ROC curve for neutrophil to lymphocyte and platelet to
lymphocyte ratios between MBOT and SCA cases
Fig. 2 Scatter graph of NLR and PLR according to the histopathological types
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Discussion
Preoperative assessment of an ovarian mass includes gy-
necologic examinations, imaging methods and tumor
markers. Despite of all these tools, postoperative patho-
logical evaluation is mandatory for the absolute diagno-
sis. Therefore, efforts are still made in order to obtain
the ideal prediction of the mass nature. Risk of malig-
nancy index (RMI) which includes ca125, ultrasound
findings and menopausal status have been developed for
this purpose. The increasing evidences emphasize the
importance of inflammation in the initiation, promotion,
invasion and metastasis of cancer [5]. It was found that
neutrophils increased and lymphocytes relatively
decreased as a result of the systemic inflammatory
response [8]. Numerous studies have demonstrated the
association between NLR and PLR with the ovarian can-
cers [4–6, 8]. In the current study, the association
between NLR and PLR with BOTs has been investigated.
A statistically significant impact for both of preoperative
NLR (p = 0,000) and PLR (p = 0,039) in distinguishing
BOTs from simple ovarian serous cysts was suggested, in
this study. Beside, hemoglobin and hematocrit values,
neutrophils, monocytes and platelets counts were evalu-
ated and then compared separately between the groups.
From these variables, merely monocytes count was not in
a statistically significant manner. On the other hand, clas-
sic markers such as age, ca125 and ultrasound findings
(septa, papillary pattern and ascites) were found to have
statistically significant difference between the groups.
Topçu et. al. reported that they found statistically sig-
nificant difference in term of age, diameter of the mass,
ca125 levels, preoperative PLR and platelet count be-
tween the benign and malignant ovarian masses,
whereas they didn’t find statistically significant effect in
term of NLR [4]. In the study by Yıldırım et. al. 316
benign and 253 malignant cases were assessed and pre-
operative NLR, PLR, and monocyte values were estab-
lished to be higher in the malignant cases. Authors
stated that NLR and PLR combined with CA-125 can be
useful for benign-malignant differentiation of the ovarian
masses [8]. Cho et al. indicated that NLR is significantly
increased in ovarian cancer cases. Moreover, it was
supposed that NLR can identify CA-125-negative cases
and predict poor outcome [9]. NLR was showed to be
associated with aggressive disease and poor survival in a
retrospective study by Williams et al. of 519 ovarian
carcinoma cases [10]. PLR were also found to be ele-
vated and correlated with poor prognosis and low sur-
vival rates in ovarian cancers by the study of Asher et.
al. [11]. Furthermore, Zhang and colleagues presumed
that preoperative PLR was superior to the other SIR
markers (CA-125, NLR, fibrinogen, CRP, and albumin)
as a predictor of survival in ovarian cancer patients [7].
Although several studies investigated the association
between preoperative NLR and PLR with invasive ovar-
ian cancers, to the best of our knowledge, there were no
reported studies in the literature which researched these
markers in the BOTs. Hence, it is deemed necessary to
conduct the present study. A simple blood count is suffi-
cient to provide these markers. These easily measured
hematological variables were considered to be useful in
discriminating BOTs from benign cysts preoperatively,
in this study. Especially, NLR and PLR were fixed to be
with an acceptable sensitivity and specificity values in
terms of predicting borderline ovarian tumors, preopera-
tively. In addition, the difference between the study and
control groups according to the classic predictors (age,
ca125, ultrasound findings such as septa, papilla and as-
cites) was found to be statistically significant. Therefore,
a novel model consisting of these classic predictors in
combined with NLR and PLR values may be promising
in identifying ovarian masses.
Conclusion
In conclusion, it seems that neutrophil to lymphocyte and
platelet to lymphocyte ratios are useful in predicting bor-
derline ovarian tumors, preoperatively. However, further
prospective, large simple-size studies should be conducted
on this subject.
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